Veracyte Announces First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- eToro to acquire TradeZero for up to $231M to expand in US
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Veracyte, Inc (VCYT) PT Lowered to $26 at Needham & Company
May 4, 2022 6:51 AM EDTNeedham & Company analyst Mike Matson lowered the price target on Veracyte, Inc (NASDAQ: VCYT) to $26.00 (from $31.00) while maintaining a Buy rating following earnings.
The analyst commented, "VCYT's 1Q22 revenue and EPS beat consensus. Organic revenue growth (excluding estimated revenue from Decipher and... More
Veracyte (VCYT) Tops Q1 EPS by 4c
May 3, 2022 4:40 PM EDTVeracyte (NASDAQ: VCYT) reported Q1 EPS of ($0.20), $0.04 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $67.8 million versus the consensus estimate of $62.32 million.
GUIDANCE:
Veracyte sees FY2022 revenue of $265-275 million, versus the consensus of $270... More
